Oncologist frets about premature decisions based on PET/CT

Article

"We need to be very rigorous about all aspects of imaging: the way FDG-PET is acquired, its analysis, and the structure of the clinical trial in which it is imbedded.

"We need to be very rigorous about all aspects of imaging: the way FDG-PET is acquired, its analysis, and the structure of the clinical trial in which it is imbedded.

"A concern we have in the treatment community is that physicians are already making decisions based on early PET assessments when we are still not clear about the optimal timing, the interpretation, and whether changing therapy (on the basis of imaging findings) affords a benefit over continuing the prior therapy.

"It is really critical not to ask too many questions in these clinical trials. We should take it one step at a time."

-Dr. Sandra Horning, a professor of medicine (oncology) at Stanford University and president of the American Society of Clinical Oncology, speaking at the 2006 Academy of Molecular Imaging meeting in Orlando.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.